sales@angenesci.com
Login | Register
logo
Structures Search
Home Other Building Blocks 3,4-Dimethoxyaniline

3,4-Dimethoxyaniline

CAS No.:
6315-89-5
Catalog Number:
AG0033IO
Molecular Formula:
C8H11NO2
Molecular Weight:
153.1784
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
5g
98%
In Stock USA
United States
$13
- +
25g
98%
In Stock USA
United States
$19
- +
100g
98%
In Stock USA
United States
$50
- +
500g
98%
In Stock USA
United States
$188
- +
Product Description
Catalog Number:
AG0033IO
Chemical Name:
3,4-Dimethoxyaniline
CAS Number:
6315-89-5
Molecular Formula:
C8H11NO2
Molecular Weight:
153.1784
MDL Number:
MFCD00008394
IUPAC Name:
3,4-dimethoxyaniline
InChI:
InChI=1S/C8H11NO2/c1-10-7-4-3-6(9)5-8(7)11-2/h3-5H,9H2,1-2H3
InChI Key:
LGDHZCLREKIGKJ-UHFFFAOYSA-N
SMILES:
COc1cc(N)ccc1OC
EC Number:
228-647-6
UNII:
XD9UJ596XD
NSC Number:
21033
UN Number:
2811
Properties
Complexity:
119  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
153.079g/mol
Formal Charge:
0
Heavy Atom Count:
11  
Hydrogen Bond Acceptor Count:
3  
Hydrogen Bond Donor Count:
1  
Isotope Atom Count:
0
Molecular Weight:
153.181g/mol
Monoisotopic Mass:
153.079g/mol
Rotatable Bond Count:
2  
Topological Polar Surface Area:
44.5A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
1.4  
Literature
Title Journal
3,4-Dimeth-oxy-N-(4-nitro-benzyl-idene)-aniline. Acta crystallographica. Section E, Structure reports online 20081101
3,4-Dimeth-oxy-N-(3-nitro-benzyl-idene)aniline. Acta crystallographica. Section E, Structure reports online 20081101
FT-IR, FT-Raman spectra and quantum chemical calculations of 3,4-dimethoxyaniline. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 20080601
Mouse N-acetyltransferase type 2, the homologue of human N-acetyltransferase type 1. Biochemical pharmacology 20080401
Cassette dosing pharmacokinetics of a library of 2,6,9-trisubstituted purine cyclin-dependent kinase 2 inhibitors prepared by parallel synthesis. Molecular cancer therapeutics 20040301
Properties